Showing 181-190 of 2366 results for "".
POINT-COUNTERPOINT: Natalizumab Extended-Interval Dosing
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/point-counterpoint-natalizumab-extended-interval-dosing/30124/Optimism vs caution for using extended-interval dosing to prevent progressive multifocal leukoencephalopathy.Improving Outcomes Earlier in Generalized Myasthenia Gravis: Roadmap for Incorporating Targeted Therapies Into Clinical Practice
https://practicalneurology.com/programs/cme/improving-outcomes-earlier-in-generalized-myasthenia-gravis-roadmap-for-incorporating-targeted-therapies-into-clinical-practice/29145/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.SmartCare: How New Technologies Are Changing the Parkinson's Spectrum
https://practicalneurology.com/diseases-diagnoses/movement-disorders/smartcare-how-new-technologies-are-changing-the-parkinsons-spectrum/30472/A Transformational Era in Stroke Care
https://practicalneurology.com/diseases-diagnoses/stroke/a-transformational-era-in-stroke-care/30221/The 2018 guidelines for treatment of acute ischemic stroke reflect great advances in patient care.Biomarkers in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/imaging-testing/biomarkers-in-multiple-sclerosis/30195/Biomarkers have resulted from breakthrough treatments and, in turn, provide targets for more breakthroughs.Amyotrophic Lateral Sclerosis with Atrophy of the Amygdala
https://practicalneurology.com/diseases-diagnoses/neuromuscular/amyotrophic-lateral-sclerosis-with-atrophy-of-the-amygdala/30444/Early and pronounced involvement of the amygdala is known to be characteristic for the behavioral variant of frontotemporal dementia, but it may also occur in ALS.Sexual Discomfort: Dealing with Dysfunction in MS and Other Neurological Conditions
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0509_01-php/30915/Sexual dysfunction can be detrimental to patients with neurodegenerative disease—especially MS. So why aren't patients—and neurologists—talking more about it?Board Re-Certification: Reform or Reboot
https://practicalneurology.com/columns/practice-management/board-re-certification-reform-or-reboot/30542/A neurologist has been leading the charge to reform MOC in neurology. He talked to Practical Neurology® about the issue.A Practical Evaluation of Migraine Trigger Site Deactivation Surgery
https://practicalneurology.com/diseases-diagnoses/headache-pain/a-practical-evaluation-of-migraine-trigger-site-deactivation/30696/An analysis of the data casts doubt on the purported benefits of MTSDS.Headache Medicine: A Crossroad of Otolaryngology, Ophthalmology, and Neurology
https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-medicine-a-crossroad-of-otolaryngology-ophthalmology-and-neurology/30611/Numerous symptoms can suggest both ophthalmological and neurological disorders.